Stockreport

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Kymera Therapeutics, Inc.  (KYMR) 
PDF WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral [Read more]